WO2022150063A1 - Homologous recombination deficiency determining method and kit thereof - Google Patents
Homologous recombination deficiency determining method and kit thereof Download PDFInfo
- Publication number
- WO2022150063A1 WO2022150063A1 PCT/US2021/046034 US2021046034W WO2022150063A1 WO 2022150063 A1 WO2022150063 A1 WO 2022150063A1 US 2021046034 W US2021046034 W US 2021046034W WO 2022150063 A1 WO2022150063 A1 WO 2022150063A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- snp loci
- loh
- hrd
- sample
- alteration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 63
- 230000007812 deficiency Effects 0.000 title claims abstract description 7
- 230000006801 homologous recombination Effects 0.000 title claims abstract description 7
- 238000002744 homologous recombination Methods 0.000 title claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 230000004075 alteration Effects 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 210000000349 chromosome Anatomy 0.000 claims description 39
- 238000012163 sequencing technique Methods 0.000 claims description 39
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 claims description 32
- 108700020462 BRCA2 Proteins 0.000 claims description 25
- 102000052609 BRCA2 Human genes 0.000 claims description 25
- 101150008921 Brca2 gene Proteins 0.000 claims description 25
- 101150020330 ATRX gene Proteins 0.000 claims description 22
- 101700002522 BARD1 Proteins 0.000 claims description 22
- 108700020463 BRCA1 Proteins 0.000 claims description 22
- 102000036365 BRCA1 Human genes 0.000 claims description 22
- 101150072950 BRCA1 gene Proteins 0.000 claims description 22
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 claims description 22
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 claims description 22
- 102100033934 DNA repair protein RAD51 homolog 2 Human genes 0.000 claims description 22
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 claims description 22
- 102100034483 DNA repair protein RAD51 homolog 4 Human genes 0.000 claims description 22
- 102000009095 Fanconi Anemia Complementation Group A protein Human genes 0.000 claims description 22
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 claims description 22
- 102000052930 Fanconi Anemia Complementation Group L protein Human genes 0.000 claims description 22
- 108700026162 Fanconi Anemia Complementation Group L protein Proteins 0.000 claims description 22
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 claims description 22
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 claims description 22
- 102100034553 Fanconi anemia group J protein Human genes 0.000 claims description 22
- 101000785776 Homo sapiens Artemin Proteins 0.000 claims description 22
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 claims description 22
- 101000712511 Homo sapiens DNA repair and recombination protein RAD54-like Proteins 0.000 claims description 22
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 claims description 22
- 101001132266 Homo sapiens DNA repair protein RAD51 homolog 4 Proteins 0.000 claims description 22
- 101100119754 Homo sapiens FANCL gene Proteins 0.000 claims description 22
- 101000848171 Homo sapiens Fanconi anemia group J protein Proteins 0.000 claims description 22
- 101000981336 Homo sapiens Nibrin Proteins 0.000 claims description 22
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 22
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims description 22
- 102100024403 Nibrin Human genes 0.000 claims description 22
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 22
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 22
- 102000001195 RAD51 Human genes 0.000 claims description 22
- 101710018890 RAD51B Proteins 0.000 claims description 22
- 108010068097 Rad51 Recombinase Proteins 0.000 claims description 22
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 22
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims description 22
- 108700042462 X-linked Nuclear Proteins 0.000 claims description 22
- 102100034552 Fanconi anemia group M protein Human genes 0.000 claims description 21
- 102100039999 Histone deacetylase 2 Human genes 0.000 claims description 21
- 101000848187 Homo sapiens Fanconi anemia group M protein Proteins 0.000 claims description 21
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 claims description 21
- 101000802948 Homo sapiens Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform Proteins 0.000 claims description 21
- 102100035728 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform Human genes 0.000 claims description 21
- 238000007481 next generation sequencing Methods 0.000 claims description 17
- 230000008685 targeting Effects 0.000 claims description 16
- 108091034117 Oligonucleotide Proteins 0.000 claims description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 12
- 101100002343 Arabidopsis thaliana ARID1 gene Proteins 0.000 claims description 11
- 238000004590 computer program Methods 0.000 claims description 11
- -1 ATR Proteins 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 claims description 8
- 208000031404 Chromosome Aberrations Diseases 0.000 claims description 8
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 claims description 8
- 239000012661 PARP inhibitor Substances 0.000 claims description 8
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 231100000005 chromosome aberration Toxicity 0.000 claims description 8
- 238000013500 data storage Methods 0.000 claims description 8
- 102000000872 ATM Human genes 0.000 claims description 7
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 230000008707 rearrangement Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 239000012623 DNA damaging agent Substances 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 238000011528 liquid biopsy Methods 0.000 claims description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 2
- 229950011068 niraparib Drugs 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical group FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000572 olaparib Drugs 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229950004707 rucaparib Drugs 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000000392 somatic effect Effects 0.000 claims description 2
- 229950004550 talazoparib Drugs 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 230000009278 visceral effect Effects 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 239000000523 sample Substances 0.000 description 54
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 16
- 238000004422 calculation algorithm Methods 0.000 description 14
- 108091093088 Amplicon Proteins 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 230000003350 DNA copy number gain Effects 0.000 description 2
- 230000004536 DNA copy number loss Effects 0.000 description 2
- 208000031448 Genomic Instability Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- 102100035631 Bloom syndrome protein Human genes 0.000 description 1
- 108091009167 Bloom syndrome protein Proteins 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100035595 Cohesin subunit SA-2 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
- 102100022302 DNA polymerase beta Human genes 0.000 description 1
- 102100029094 DNA repair endonuclease XPF Human genes 0.000 description 1
- 102100039116 DNA repair protein RAD50 Human genes 0.000 description 1
- 102100027830 DNA repair protein XRCC2 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102100033996 Double-strand break repair protein MRE11 Human genes 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 description 1
- 108010027673 Fanconi Anemia Complementation Group C protein Proteins 0.000 description 1
- 102000013601 Fanconi Anemia Complementation Group D2 protein Human genes 0.000 description 1
- 108010026653 Fanconi Anemia Complementation Group D2 protein Proteins 0.000 description 1
- 102000010634 Fanconi Anemia Complementation Group E protein Human genes 0.000 description 1
- 108010077898 Fanconi Anemia Complementation Group E protein Proteins 0.000 description 1
- 102000012216 Fanconi Anemia Complementation Group F protein Human genes 0.000 description 1
- 108010022012 Fanconi Anemia Complementation Group F protein Proteins 0.000 description 1
- 102000007122 Fanconi Anemia Complementation Group G protein Human genes 0.000 description 1
- 108010033305 Fanconi Anemia Complementation Group G protein Proteins 0.000 description 1
- 102100031885 General transcription and DNA repair factor IIH helicase subunit XPB Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000642968 Homo sapiens Cohesin subunit SA-2 Proteins 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 101000927847 Homo sapiens DNA ligase 3 Proteins 0.000 description 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 1
- 101000902539 Homo sapiens DNA polymerase beta Proteins 0.000 description 1
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 description 1
- 101000649306 Homo sapiens DNA repair protein XRCC2 Proteins 0.000 description 1
- 101000591400 Homo sapiens Double-strand break repair protein MRE11 Proteins 0.000 description 1
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 description 1
- 101000920748 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPB Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 1
- 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 description 1
- 101000807344 Homo sapiens Ubiquitin-conjugating enzyme E2 A Proteins 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 description 1
- 102100033284 Leucine-rich repeats and immunoglobulin-like domains protein 3 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229910015837 MSH2 Inorganic materials 0.000 description 1
- 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 description 1
- 229920006068 Minlon® Polymers 0.000 description 1
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 description 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 1
- 101100355599 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-11 gene Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 101150006234 RAD52 gene Proteins 0.000 description 1
- 102000053062 Rad52 DNA Repair and Recombination Human genes 0.000 description 1
- 108700031762 Rad52 DNA Repair and Recombination Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102100037261 Ubiquitin-conjugating enzyme E2 A Human genes 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000010255 female reproductive organ cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 201000006879 hepatobiliary system cancer Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000012110 pancreatic exocrine neoplasm Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000004435 urinary system cancer Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 108010073629 xeroderma pigmentosum group F protein Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Definitions
- the disclosure relates to a method and a kit for assessing homologous recombination deficiency (HRD) status.
- HRD homologous recombination deficiency
- PARPs Poly (ADP-ribose) polymerases
- HRR homologous recombination repair
- Inhibition of PARP may cause unrepaired DNA single-strand breaks (SSBs) and stalled replication forks accumulate, resulting in collapse of replication forks and generation of double-strand DNA breaks (DSBs) during DNA replication, which are repaired by HRR pathway in normal cells.
- HRR homologous recombination deficiency
- HRD homologous recombination deficiency
- the disclosure relates to a method for assessing homologous recombination deficiency (HRD) status in a subject, including:
- SNP loci of a sample from the subject, wherein at least 50% of interval between every two neighboring SNP loci is 0.01 to 1 Mb in length;
- LOH score is a ratio of the number of LOH SNP loci to the number of non-homozygous SNP loci
- SNP loci is at least 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 110000, 120000, 130000, 140000, 150000, 160000, 170000, 180000, 190000, 200000, 210000, 220000, 230000, 240000, 250000, 260000, 270000, 280000, 290000, or 300000 loci in number.
- the SNP loci is 1000 to 260000, 2000 to 200000, 3000 to 100000, 3000 to 60000, 6000 to 11000, 7000 to 10000, or 7500 to 9500 in number. In some embodiments, the SNP loci are in at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 pairs of human chromosomes. In some embodiments, the SNP loci are in autosomal chromosomes.
- the SNP loci are at lp, 2p, 3p, 4p, 5p, 6p, 7p, 8p, 9p, lOp, lip, 12p, 16p, 17p, 18p, 19p, 20p, 21p, 22p, lq, 2q, 3q, 4q, 5q, 6q, 7q, 8q, 9q, lOq, llq, 12q, 13q, 14q, 15q, 16q, 17q, 18q, 19q, 20q, 21 q, and/or 22q of human chromosomal arms.
- At least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of intervals between the SNP loci is 0.01 to 3 Mb, 0.02 to 2 Mb, 0.03 to 1 Mb, 0.06 to 1 Mb, 0.1 to 1 Mb, 0.1 to 0.5 Mb, or 0.06 to 0.6 Mb in length.
- the mean of intervals between the SNP loci is 0.01 to 3 Mb, 0.02 to 2 Mb, 0.03 to 1 Mb, 0.06 to 1 Mb, 0.1 to 1 Mb, 0.06 to 0.6 Mb, 0.1 to 0.5 Mb, or 0.2 to 0.4 Mb in length.
- the chromosomal aberration is loss of heterozygosity (LOH).
- the HRD score is the LOH score.
- the LOH score is a ratio of the number of non-homozygous SNP loci with the chromosomal aberration to the number of non-homozygous SNP loci.
- the LOH score is a ratio of the number of LOH SNP loci to the number of non-homozygous SNP loci.
- the non- homozygous SNP loci include the heterozygous SNP loci and LOH SNP loci.
- the heterozygous SNP loci are identified from the SNP loci.
- the LOH score is adjusted through eliminating imbalanced chromosome arms.
- the LOH score is a ratio of the number of LOH SNP loci in non-imbalanced chromosome arms to the number of the non- homozygous SNP loci in non-imbalanced chromosome arms.
- the imbalanced chromosome arm is characterized by a predetermined ratio of the number of LOH SNP loci to the number of the non-homozygous SNP loci in a chromosome arm, wherein the predetermined ratio is at least 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
- the ratio of the non-homozygous SNP loci with LOH for characterizing the imbalanced chromosome arm is adjusted based on the value of tumor purity of the sample.
- the ratio of the non- homozygous SNP loci with LOH for identifying imbalanced chromosome arm is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100%.
- the value of the tumor purity is between 30% to 95% or 30% to 70%.
- the value of the tumor purity is 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
- the HRD status is identified as positive or negative.
- a cutoff value of the LOH score for identifying HRD status is 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, or 0.6.
- the disclosure relates to a method for assessing HRD status in a subject, including:
- the invention relates to a method for assessing HRD status in a subject, comprising:
- the HRD status is identified as positive when at least one of the gene harbors an alteration. In some embodiments, the HRD status is identified as negative when none of the gene harbors an alteration.
- the alteration is selected from the group consisting of single nucleotide variant (SNV), insertion, deletion, amplification, gene fusion, and rearrangement.
- the alteration is selected from the group consisting of SNV, small insertions and deletion (INDEL), large genomic rearrangement (LGR), and copy number variation (CNV).
- the alteration is a germline alteration or a somatic alteration.
- the invention relates to a method for assessing HRD status in a subject, including: (1) sequencing the genes including BRCA1, BRCA2, ARID! A, ATM, ATR, ATRX, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, FANCM, HDAC2, NBN, PALB2, PPP2R2A, PTEN, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or any combination thereof;
- the method further comprises a step of identifying a treatment based on the HRD status for the subject and/ or administering a therapeutically effective amount of a treatment to the subject.
- the treatment includes administering the drug including but not limited to a DNA damaging agent, an anthracycline, a topoisomerase I inhibitor, radiation, and/ or a PARP inhibitor or any combination thereof.
- the PARP inhibitor includes but not limited to olaparib, niraparib, rucaparib, and talazoparib.
- the method for assessing HRD status in a sample is implemented on a next-generation sequencing (NGS) computing platform.
- the sample is sequenced by NGS assay.
- the NGS system used in the NGS assay is including but not limited to the MiSeq, HiSeq, MiniSeq, iSeq, NextSeq and NovaSeq sequencers manufactured by Illumina, Inc., Ion Personal Genome Machine (PGM), Ion Proton, Ion S5 series and Ion GeneStudio S5 series manufactured by Life Technologies, Inc., BGlseq series, DNBseq series and MGIseq series, manufactured by BGI, and MinlON/PromethlON sequencers manufactured by Oxford Nanopore Technologies.
- PGM Personal Genome Machine
- Ion Proton Ion S5 series
- Ion GeneStudio S5 series manufactured by Life Technologies, Inc.
- BGlseq series, DNBseq series and MGIseq series manufactured by B
- the sequencing reads are generated from nucleic acids that are amplified from the original sample or the nucleic acids captured by the bait. In some embodiments, the sequencing reads are generated from a sequencer that required the addition of an adapter sequence. In some embodiments, the sequencing reads are generated from a method includes but not limited to hybrid capture, primer extension target enrichment, a molecular inversion probe-based method, or multiplex target-specific PCR.
- the sample originates from cell line, biopsy, primary tissue, frozen tissue, formalin-fixed paraffin-embedded (FFPE), liquid biopsy, blood, serum, plasma, buffy coat, body fluid, visceral fluid, ascites, paracentesis, cerebrospinal fluid, saliva, urine, tears, seminal fluid, vaginal fluid, aspirate, lavage, buccal swab, peripheral blood mononuclear cells (PBMC), circulating tumor cell (CTC), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), DNA, nucleic acid, purified nucleic acid, or purified DNA.
- PBMC peripheral blood mononuclear cells
- CTC circulating tumor cell
- cfDNA cell-free DNA
- ctDNA circulating tumor DNA
- the sample originates from a human subject. In some embodiments, the sample is a clinical sample. In some embodiments, the sample originates from a diseased patient. In some embodiments, the sample originates from a patient having cancer, solid tumor, or hematologic malignancy.
- the sample originates from a patient having ovarian cancer, prostate cancer, breast cancer, or pancreatic cancer in some embodiments, the sample originates from a patient having brain cancer, breast cancer, colon cancer, endocrine gland cancer, esophageal cancer, female reproductive organ cancer, head and neck cancer, hepatobiliary system cancer, kidney cancer, lung cancer, mesenchymal cell neoplasm, prostate cancer, skin cancer, stomach cancer, tumor of exocrine pancreas, or urinary system cancer.
- the sample originates from a pregnant woman, a child, an adolescent, an elder, or an adult.
- the sample is a research sample.
- the method further includes a step of outputting the HRD status to an electronic storage medium or a display.
- the disclosure relates to a method for assessing HRD status in a subject implemented on a NGS computing platform, including: (1) assaying an alteration of the genes of the sample from the subject, including:
- the invention relates to a method for assessing HRD status in a subject implemented on a NGS computing platform, including:
- the HRD status is identified as positive either at least one of the gene harbors an alteration or the score (i.e., the LOH score or the HRD score) is greater than a cutoff value.
- the invention in another general aspect, relates to a system for assessing HRD status, and the system comprises a data storage device storing instructions for determining characteristics of HRD status and a processor configured to execute the instructions to perform a method including:
- SNP single nucleotide polymorphism
- LOH loss of heterozygosity
- the invention in another general aspect, relates to a system for assessing HRD status, and the system includes a data storage device storing instructions for determining characteristics of HRD status and a processor configured to execute the instructions to perform a method including:
- the invention in another general aspect, relates to a system for assessing HRD status, and the system comprises a data storage device storing instructions for determining characteristics of HRD status and a processor configured to execute the instructions to perform a method including:
- the invention in another general aspect, relates to a system for assessing HRD status, and the system comprises a data storage device storing instructions for determining characteristics of HRD status and a processor configured to execute the instructions to perform a method including:
- the invention relates to a kit for assessing HRD status in a sample, including:
- the invention relates to a kit for assessing HRD status in a sample, including:
- a reagent including: a set of oligonucleotides targeting a plurality of SNP loci, wherein there is an interval between every two neighboring SNP loci and at least 50% of the interval are 0.01 to 1 Mb in length;
- (2) a computer program including: instructions to calculate a LOH score, wherein the LOH score is a ratio of the number of LOH SNP loci to the number of non-homozygous SNP loci; and instructions to identify HRD status.
- the invention relates to a kit for assessing HRD status in a sample, including:
- a reagent including: a set of oligonucleotides targeting the genes including BRCA1, BRCA2, ARID1 A, ATM, ATR, ATRX, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, FANCM, HDAC2, NBN, PALB2, PPP2R2A, PTEN, RAD51, RAD51B, RAD51C, RAD51D, RAD54L genes or any combination thereof;
- the invention relates to a kit for assessing HRD status in a sample, including:
- a reagent including: a set of oligonucleotides targeting a plurality of SNP loci, wherein there is an interval between every two neighboring SNP loci and at least 50% of the interval are 0.01 to 1 Mb in length ; and a set of oligonucleotides targeting at least one HRR-associated gene;
- (2) a computer program including: instructions to calculate a LOH score, wherein the LOH score is a ratio of the number of LOH SNP loci to the number of non-homozygous SNP loci; and identifying HRD status; instructions to determine whether any of the HRR-associated genes harbors an alteration; and instructions to identify HRD status.
- the invention relates to a kit for assessing HRD status in a sample, including:
- a reagent including: a set of oligonucleotides targeting a plurality of SNP loci of the sample; and a set of oligonucleotides targeting the genes including BRCA1, BRCA2, ARID1 A, ATM, ATR, ATRX, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, FANCM, HDAC2, NBN, PALB2, PPP2R2A, PTEN, RAD51, RAD51B, RAD51C, RAD51D, RAD54L genes or any combination thereof;
- a computer program including: instructions to calculate a HRD score of chromosomal aberration; instructions to determine whether any of the BRCA1, BRCA2, ARID1 A, ATM, ATR, ATRX, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, FANCM, HDAC2, NBN, PALB2, PPP2R2A, PTEN, RAD51, RAD51B, RAD51C, RAD51D, and RAD54L genes harbors an alteration; and instructions to identify HRD status.
- the computer program further includes instructions to identify a treatment based on the HRD status for the subject.
- Fig. 1A-1D show stability of LOH score of different algorithms at a different number of SNP loci of two tumor samples (GSM956523 and GSM956527) and two normal samples (GSM956582 and GSM956597).
- Fig. 2A shows the LOH score of different tumor groups and normal sample groups using Equation 1 at a different number of SNP loci.
- Fig. 2B shows the LOH score of different tumor groups and normal sample groups using Equation 2 at a different number of SNP loci.
- Fig. 3 shows LOH score at different tumor purity levels considering or ignoring chromosome arm imbalance factor.
- Fig. 4 is a graph plotting length of the interval between the SNP loci.
- Fig. 5 is a graph plotting the LOH distribution of different groups.
- HRR-associated gene refers to an HRR gene or a regulator or a modulator thereof.
- the alteration of the HRR-associated gene may cause the presence of HRD.
- the HRR-associated gene is selected from the group consisting of BRCA1, BRCA2, ARID1 A, ATM, ATR, ATRX, ABL1, BAP1, BARD1, BLM, BRIP1, CDK12, CHEK1, CHEK2, ERCC1, ERCC3, ERCC4, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, LIG3, MRE11, MSH2, MSH6, MLH1, NBN, PALB2, PTEN, PARP1, POLB, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, UBE2A, XRCC2, DNMT3A, IDH1, IDH2, STAG2, and TP53 genes.
- the HRR-associated gene is selected from the group consisting of BRCA1, BRCA2, ARID1A, ATM, ATR, ATRX, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, FANCM, HDAC2, NBN, PALB2, PPP2R2A, PTEN, RAD51, RAD51B, RAD51C, RAD51D, and RAD54L genes.
- cutoff value refers to a numerical value or other representation whose value is used to arbitrate between two or more states of classification for a biological sample. In some embodiments of the invention, the cutoff value is used to distinguish positive or negative HRD status. If the HRD score is greater than the cutoff value, the HRD status is determined as positive; or if the HRD score is less than the cutoff value, the HRD status is determined as negative.
- an imbalanced chromosome arm means copy number loss or gain of the chromosome arm.
- an imbalanced chromosome arm refers to a chromosome arm with at least 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the non-homozygous SNP loci with LOH.
- tumor purity is the proportion of cancer cells in a tumor sample. Tumor purity impacts the accurate assessment of molecular and genomics features as assayed with NGS approaches.
- the sample has a tumor purity at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100%.
- depth refers to the number of sequencing reads per location.
- mean depth refers to the average number of reads across the entire sequencing region.
- the mean depth has an impact on the performance of the NGS assay. The higher the mean depth, the lower the variability in the variant frequency of the variant.
- the mean depth of the sample across the entire sequencing region is at least 200x, 300x, 400, 500x, 600x, 700x, 800x, 900x, lOOOx, 2000x, 3000x, 4000x, 5000x, 6000x, 8000x, lOOOOx, or 20000x.
- coverage refers to the depth at a given locus.
- Target base coverage refers to the percentage of the sequenced region that is sequenced at a depth above a predefined value. Target base coverage needs to specify the depth at which it is evaluated. In some embodiments, the target base coverage at lOOx is 85% . That means 85% of the target sequenced bases are covered by at least lOOx depth sequencing reads.
- the target base coverage at 30x, 40x, 50x, 60x, 70x, 80x, 90x, lOOx, 125x, 150x, 175x, 200x, 300x, 400x, 500x, 750x, lOOOx is above 70%, 75%, 80%, 85%, 90%, or 95%.
- subject or “human subject” refers to those with formally diagnosed disorders, those without formally recognized disorders, those receiving medical attention, those at risk of developing the disorders, etc.
- treat includes therapeutic treatments, prophylactic treatments, and applications in which one reduces the risk that a subject will develop a disorder or other risk factor. Treatment does not require the complete curing of a disorder and encompasses embodiments in which one reduces symptoms or underlying risk factors.
- therapeutically effective amount means an amount of a therapeutically active molecule needed to elicit the desired biological or clinical effect.
- a therapeutically effective amount is the amount of drug needed to treat cancer patients with HRD positive.
- Example 1 Stability test of algorithms for LOH scoring
- Equation 1 considered the number of LOH SNPs, which calculated the LOH score by the ratio of the number of the loss of heterozygosity SNPs to the number of non-homozygous SNPs.
- Equation 2 considered the total length of LOH SNPs, which determined the LOH score by the ratio of the total length of loss of heterozygosity SNP regions to the genome size. The analysis was performed using R (version 4.0.0). number of LOH SNPs
- Figs. 1A-1D show the LOH scoring results of two tumor samples (GSM956523 and GSM956527) and two normal samples (GSM956582 and GSM956597) using two different algorithms.
- the calculation results of using Equation 1 show a stable median LOH score at a different number of SNP loci when the LOH score derived from Equation 2 is descending as the number of SNP loci decreases.
- This study selects an algorithm that estimates LOH score having significant differences between tumor and normal groups at a different number of SNP loci.
- All samples used in the study were analyzed in this study [Wang, Birkbak, et al., 2012] Tumor samples with BRCA2 LOH were clustered to the high genomic instability group (GI-H), and in contrast, the low instability group (GI-L) was the tumor samples without BRCA2 LOH. Since cells with BRCA2 LOH demonstrated genomic instability and showed high sensitivity to DNA damaging agents, GI-H group in this study could potentially represent drug sensitive group, and GI-L group could potentially represent drug-resistant groups. There were 12, 11, and 18 samples in GI-H, GI-L, and normal groups, respectively.
- LOH score of each sample was estimated by Equation 1 and Equation 2 described in Example 1 at the number of SNP loci of 260K, 50K, 10K, 7K, 5K, 3K, 2K, and IK. Wilcoxon signed-rank test was applied to estimate the p- value of LOH score between GI-H, GI-L, and normal samples.
- Example 3 LOH scoring for samples at different tumor purity levels with or without considering chromosome arm imbalance factor
- a cancer cell line sample (NCL-H1395) with copy number alteration was mixed with its match-normal sample to mimic different tumor purity levels.
- the experimental procedure includes DNA extraction, library construction and NGS sequencing are in accordance with Example 5.
- LOH scores of the mixed sample was estimated by three different algorithms at different tumor purity levels. The first algorithm calculated the LOH score without considering the impact of chromosome arm imbalance (Equation 1). The second and third algorithms considered the chromosome arm imbalance factor, which excluded the SNPs located on the imbalanced chromosome arms (Equation 3).
- the imbalanced chromosome arm is characterized by a ratio of the number of LOH SNP loci to the number of the non-homozygous SNP loci in a chromosome arm.
- the ratio in this example is 85% .
- the third algorithm further adjusted the ratio of the non- homozygous SNP loci with LOH for characterizing imbalanced chromosome arms based on different tumor purity levels. number of LOH SNPs in non- imbalanced chromosome arms
- LOH number of non-homozygous SNPs in non-imbalanced chromosome arms
- Fig. 3 shows the LOH scoring results using three different algorithms at different tumor purity levels.
- the LOH scores calculated by the first algorithm are increasing sharply along with the increased tumor purity.
- the LOH scores calculated by the second and the third algorithms are stable when the tumor purity is larger than 30% .
- Example 4 Determining HRD status of cancer samples
- An amplicon-based NGS panel was designed targeting the coding regions of
- Panel A including ARID1A, ATM, ATR, ATRX, BARD1, BRCA1, BRCA2, BRIP1,
- CDK12 CDK12, CHEK1, CHEK2, FANCA, FANCL, FANCM, HDAC2, NBN, PALB2,
- PPP2R2A PTEN, RAD51, RAD51B, RAD51C, RAD51D, and RAD54L, and about
- FFPE samples and PBMC from cancer patients were collected and assayed using the NGS panel.
- Genomic DNA was extracted using RecoverAllTM Total Nucleic Acid Isolation Kit (Thermo Fisher Scientific).
- NGS library was constructed following the user guide of CleanPlex NGS panel (Paragon Genomics, USA). Briefly, 60ng DNA was amplified by multiplex PCR reaction using primers targeting the region designed above. After purification using magnetic beads, CP digestion, and second purification, a second PCR reaction was performed using the i5 and i7 indexing primer for Illumina following the user guide. After another purification, samples were run through capillary electrophoresis (FragmentAnalyzer, AATI). Samples that pass library qualify control (QC) are combined for sequencing on NextSeq550 (Illumina, USA) following the manufacturer's system guide and Illumina NextSeq System Denature and Dilute Fibraries Guide.
- NextSeq550 Illumina, USA
- Samples QC was performed to make sure that the mean sequencing depth of each sample reached lOOOx.
- amplicons with read counts in the lowest 1st percentile and highest 0.5 percentile of all detectable amplicons and amplicons with a coefficient of variation > 0.35 were removed. The remaining amplicons were normalized to correct the pool design bias.
- ONCOCNV an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014
- ONCOCNV was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. Observed copy numbers of each gene and exon were calculated using ONCOCNV.
- ADTEx Aberration Detection in Tumour Exome
- SNPs were determined as LOH or heterozygous according to their variant allele frequencies.
- the LOH score of a sample is calculated by taking the proportion of SNPs with LOH status according to Equation 3.
- chromosome arm imbalance When there is chromosome arm imbalance detected, all SNPs on the chromosome arm are excluded from the analysis. Here, chromosome arm imbalance is detected as either a copy number gain or loss for the entire chromosome arm.
- Example 5 LOH distribution of samples in different genotype groups
- This study was designed to evaluate the LOH score distribution of samples with different genotypes of Panel A, including ARID! A, ATM, ATR, ATRX, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, FANCM, HDAC2, NBN, PALB2, PPP2R2A, PTEN, RAD51, RAD51B, RAD51C, RAD51D, and RAD54L.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180004123.0A CN114096681A (en) | 2021-01-10 | 2021-08-13 | Homologous recombination deletion detection method and reagent set thereof |
JP2023541639A JP2024502611A (en) | 2021-01-10 | 2021-08-13 | Method and kit for determining homologous recombination repair deficiency |
US18/346,875 US20240026462A1 (en) | 2021-01-10 | 2021-08-13 | Homologous recombination deficiency determining method and kit thereof |
EP21766325.1A EP4274908A1 (en) | 2021-01-10 | 2021-08-13 | Homologous recombination deficiency determining method and kit thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163135622P | 2021-01-10 | 2021-01-10 | |
US63/135,622 | 2021-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022150063A1 true WO2022150063A1 (en) | 2022-07-14 |
Family
ID=77655684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/046034 WO2022150063A1 (en) | 2021-01-10 | 2021-08-13 | Homologous recombination deficiency determining method and kit thereof |
Country Status (2)
Country | Link |
---|---|
TW (1) | TWI817178B (en) |
WO (1) | WO2022150063A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013096843A1 (en) * | 2011-12-21 | 2013-06-27 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
WO2016025958A1 (en) * | 2014-08-15 | 2016-02-18 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
US20190130997A1 (en) * | 2016-05-01 | 2019-05-02 | Genome Research Limited | Method of characterising a dna sample |
-
2021
- 2021-08-13 WO PCT/US2021/046034 patent/WO2022150063A1/en active Application Filing
- 2021-08-16 TW TW110130068A patent/TWI817178B/en active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013096843A1 (en) * | 2011-12-21 | 2013-06-27 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
WO2016025958A1 (en) * | 2014-08-15 | 2016-02-18 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
US20190130997A1 (en) * | 2016-05-01 | 2019-05-02 | Genome Research Limited | Method of characterising a dna sample |
Non-Patent Citations (3)
Title |
---|
GOU RUI ET AL: "Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy", LIFE SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 261, 14 September 2020 (2020-09-14), XP086319736, ISSN: 0024-3205, [retrieved on 20200914], DOI: 10.1016/J.LFS.2020.118434 * |
HAUNSCHILD CAROLYN E ET AL: "The current landscape of molecular profiling in the treatment of epithelial ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 160, no. 1, 11 October 2020 (2020-10-11), pages 333 - 345, XP086431075, ISSN: 0090-8258, [retrieved on 20201011], DOI: 10.1016/J.YGYNO.2020.09.043 * |
O'KANE GRAINNE M ET AL: "Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer", TRENDS IN MOLECULAR MEDICINE, vol. 23, no. 12, 10 November 2017 (2017-11-10), pages 1121 - 1137, XP085289193, ISSN: 1471-4914, DOI: 10.1016/J.MOLMED.2017.10.007 * |
Also Published As
Publication number | Publication date |
---|---|
TW202227642A (en) | 2022-07-16 |
TWI817178B (en) | 2023-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zheng et al. | Comprehensive pan-genomic characterization of adrenocortical carcinoma | |
US9965585B2 (en) | Detection of genetic or molecular aberrations associated with cancer | |
Villani et al. | The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations | |
CN103270176A (en) | Method for discovering pharmacogenomic biomarkers | |
WO2018231957A1 (en) | Tumor mutation burden | |
Guay et al. | A study in familial hypercholesterolemia suggests reduced methylomic plasticity in men with coronary artery disease | |
WO2019008148A9 (en) | Enrichment of targeted genomic regions for multiplexed parallel analysis | |
EP4013895A1 (en) | Molecular predictors of patient response to radiotherapy treatment | |
US20240026462A1 (en) | Homologous recombination deficiency determining method and kit thereof | |
AU2020201081A1 (en) | Detection of genetic or molecular aberrations associated with cancer | |
WO2022150063A1 (en) | Homologous recombination deficiency determining method and kit thereof | |
US20220127601A1 (en) | Method of determining the origin of nucleic acids in a mixed sample | |
WO2021257926A1 (en) | Microsatellite instability determining method and system thereof | |
US20240052424A1 (en) | Methods for classifying a sample into clinically relevant categories | |
US20240052416A1 (en) | Methods for classiying a sample into clinically relevant categories | |
CN109136371B (en) | A kind of radiotherapy effect and the combination of toxic reaction related gene, detection probe library and detection kit | |
McGregor | A Tale of Two Validations: Molecular Diagnostic Assays for the Detection of Clinically Significant Alterations | |
CN117402974A (en) | Biomarker, kit and method for detecting intestinal cancer microsatellite instability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21766325 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023541639 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021766325 Country of ref document: EP Effective date: 20230810 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202304539Y Country of ref document: SG |